1. Home
  2. PIII vs NSRX Comparison

PIII vs NSRX Comparison

Compare PIII & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo P3 Health Partners Inc.

PIII

P3 Health Partners Inc.

N/A

Current Price

$4.29

Market Cap

33.8M

Sector

Health Care

ML Signal

N/A

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

HOLD

Current Price

$3.50

Market Cap

37.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PIII
NSRX
Founded
2015
2019
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.8M
37.1M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
PIII
NSRX
Price
$4.29
$3.50
Analyst Decision
Buy
Buy
Analyst Count
2
2
Target Price
$18.00
★ $19.67
AVG Volume (30 Days)
11.5K
★ 23.8K
Earning Date
11-09-2026
08-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $1,459,080,000.00
N/A
Revenue This Year
$6.32
N/A
Revenue Next Year
$9.37
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.52
$1.98
52 Week High
$16.89
$9.50

Technical Indicators

Market Signals
Indicator
PIII
NSRX
Relative Strength Index (RSI) 28.39 50.98
Support Level $2.39 $2.97
Resistance Level $11.55 $3.60
Average True Range (ATR) 0.49 0.27
MACD 0.06 -0.01
Stochastic Oscillator 16.82 48.14

Price Performance

Historical Comparison
PIII
NSRX

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: